Carmine De Angelis

10PUBLICATIONS
97CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersMetabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 13, 2025
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Giuseppe Di Grazia, Arianna Dri, Angela Grieco

|Jul 01, 2025
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER).

Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi

|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Anran Chen, Beom-Jun Kim, Aparna Mitra

|Feb 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.

Cristina Guarducci, Agostina Nardone, Douglas Russo

|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis

|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath

Pageof 2

Frequent Collaborators

6 joint publications

Rachel Schiff

3 joint publications

Jamunarani Veeraraghavan

3 joint publications

Mothaffar F Rimawi

2 joint publications

Fabio Puglisi